<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34145550</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0305</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Molecular biotechnology</Title><ISOAbbreviation>Mol Biotechnol</ISOAbbreviation></Journal><ArticleTitle>COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.</ArticleTitle><Pagination><MedlinePgn>885-897</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12033-021-00353-4</ELocationID><Abstract><AbstractText>COVID-19 pandemic caused by SARS-CoV-2 globally impacted the humanity causing tragic outcomes; costing millions of lives, destroying economies and demolishing public health infrastructures. The emergence of vaccines using various ingenious approaches in less than a year was deemed the light at the end of the tunnel. However, recent emergence of variants of SARS-CoV-2 in several parts of the world revealed that another hurdle is ahead in the fight against COVID-19. This review will highlight how SARS-CoV-2 mutations, creating different virus variants could potentially impact virus pathogenesis as well as different therapy approaches and vaccine design.</AbstractText><CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volkan</LastName><ForeName>Ender</ForeName><Initials>E</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0071-5028</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Cyprus International University, via Mersin 10, 99258, Nicosia, Northern Cyprus, Turkey. evolkan@ciu.edu.tr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biotechnology Research Center, Cyprus International University, via Mersin 10, 99258, Nicosia, Northern Cyprus, Turkey. evolkan@ciu.edu.tr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Biotechnol</MedlineTA><NlmUniqueID>9423533</NlmUniqueID><ISSNLinking>1073-6085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34145550</ArticleId><ArticleId IdType="doi">10.1007/s12033-021-00353-4</ArticleId><ArticleId IdType="pii">10.1007/s12033-021-00353-4</ArticleId><ArticleId IdType="pmc">PMC8213040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., Lui, S. F., Szeto, C. C., Chung, S., &amp; Sung, J. J. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine, 348(20), 1986–1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., Wong, P. C., Lam, B., Ip, M. S., Chan, J., Yuen, K. Y., &amp; Lai, K. N. (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine, 348(20), 1977–1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., &amp; Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine, 367(19), 1814–1820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., … Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273.</Citation><ArticleIdList><ArticleId IdType="pubmed">7095418</ArticleId><ArticleId IdType="pmcid">7095418</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta, D., &amp; Vanelli, M. (2020). WHO declares COVID-19 a pandemic. Acta Bio-Medica, 91(1), 157–160.</Citation><ArticleIdList><ArticleId IdType="pubmed">32191675</ArticleId><ArticleId IdType="pmcid">7569573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan, A. O., Kafai, N. M., Dmitriev, I. P., Fox, J. M., Smith, B. K., Harvey, I. B., Chen, R. E., Winkler, E. S., Wessel, A. W., Case, J. B., Kashentseva, E., McCune, B. T., Bailey, A. L., Zhao, H., VanBlargan, L. A., Dai, Y. N., Ma, M., Adams, L. J., Shrihari, S., … Diamond, M. S. (2020). A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell, 183(1), 169–184 e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">32931734</ArticleId><ArticleId IdType="pmcid">7437481</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.08.026</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit, E., van Doremalen, N., Falzarano, D., &amp; Munster, V. J. (2016). SARS and MERS: Recent insights into emerging coronaviruses. Nature Reviews Microbiology, 14(8), 523–534.</Citation><ArticleIdList><ArticleId IdType="pubmed">27344959</ArticleId><ArticleId IdType="pmcid">7097822</ArticleId><ArticleId IdType="doi">10.1038/nrmicro.2016.81</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Marzi, A., &amp; Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 5(4), 562–569.</Citation><ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId><ArticleId IdType="doi">10.1038/s41564-020-0688-y</ArticleId><ArticleId IdType="pmcid">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., &amp; Pohlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280 e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7102627</ArticleId><ArticleId IdType="pmcid">7102627</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy, S. (2018). Why are RNA virus mutation rates so damn high? PLoS Biology, 16(8), e3000003.</Citation><ArticleIdList><ArticleId IdType="pubmed">30102691</ArticleId><ArticleId IdType="pmcid">6107253</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.3000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevajol, M., Subissi, L., Decroly, E., Canard, B., &amp; Imbert, I. (2014). Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Research, 194, 90–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">25451065</ArticleId><ArticleId IdType="pmcid">7114481</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2014.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama, T., Platt, D., &amp; Parida, L. (2020). Variant analysis of SARS-CoV-2 genomes. Bulletin of the World Health Organization, 98(7), 495–504.</Citation><ArticleIdList><ArticleId IdType="pubmed">32742035</ArticleId><ArticleId IdType="pmcid">7375210</ArticleId><ArticleId IdType="doi">10.2471/BLT.20.253591</ArticleId></ArticleIdList></Reference><Reference><Citation>Oreshkova, N., Molenaar, R. J., Vreman, S., Harders, F., Oude Munnink, B. B., Hakze-van der Honing, R. W., Gerhards, N., Tolsma, P., Bouwstra, R., Sikkema, R. S., Tacken, M. G., de Rooij, M. M., Weesendorp, E., Engelsma, M. Y., Bruschke, C. J., Smit, L. A., Koopmans, M., van der Poel, W. H., &amp; Stegeman, A. (2020). SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Eurosurveillance, 25(23), 2001005.</Citation><ArticleIdList><ArticleId IdType="pmcid">7403642</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.23.2001005</ArticleId></ArticleIdList></Reference><Reference><Citation>England, P. H. (2020). Investigation of novel SARS-CoV-2 variant: Variant of concern 202012/01, technical briefing 3.</Citation></Reference><Reference><Citation>Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., … de Oliveira, T. (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. https://doi.org/10.1101/2020.12.21.20248640 .</Citation></Reference><Reference><Citation>Voloch, C. M., da Silva Francisco, R., Jr., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimaraes, A. P. C., Mariani, D., da Costa, R. M., Ferreira, O. C., Jr., L.W.A.C.C. Covid19-Ufrj Workgroup, Frauches, T. S., de Mello, C. M. B., Leitao, I. C., Galliez, R. M., Faffe, D. S., Castineiras, T., Tanuri, A., &amp; de Vasconcelos, A. T. R. (2021). Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. Journal of Virology. https://doi.org/10.1128/JVI.00119-21 .</Citation></Reference><Reference><Citation>Santos, J. C., &amp; Passos, G. A. (2021). The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation. bioRxiv. https://doi.org/10.1101/2020.12.29.424708 .</Citation></Reference><Reference><Citation>Tu, H., Avenarius, M. R., Kubatko, L., Hunt, M., Pan, X., Ru, P., Garee, J., Thomas, K., Mohler, P., Pancholi, P., &amp; Jones, D. (2021). Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio. bioRxiv. https://doi.org/10.1101/2021.01.12.426407 .</Citation></Reference><Reference><Citation>Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Zhang, L., Li, X., Huang, W., &amp; Wang, Y. (2020). The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell, 182(5), 1284–1294 e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7366990</ArticleId><ArticleId IdType="pmcid">7366990</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., &amp; Tada, T. (2021). B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv. https://doi.org/10.1101/2021.03.24.436620 .</Citation></Reference><Reference><Citation>Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., … Shi, P. Y. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 592(7852), 116–121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2895-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan, C., Yao, Y. F., Yang, X. L., Zhou, Y. W., Gao, G., Peng, Y., Yang, L., Hu, X., Xiong, J., Jiang, R. D., Zhang, H. J., Gao, X. X., Peng, C., Min, J., Chen, Y., Si, H. R., Wu, J., Zhou, P., Wang, Y. Y., … Yuan, Z. M. (2020). Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Research, 30(8), 670–677.</Citation><ArticleIdList><ArticleId IdType="pubmed">32636454</ArticleId><ArticleId IdType="pmcid">7364749</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-0364-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans, M. (2021). SARS-CoV-2 and the human-animal interface: Outbreaks on mink farms. The Lancet Infectious Diseases, 21(1), 18–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">33227234</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30912-9</ArticleId><ArticleId IdType="pmcid">33227234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D. L., Volz, E., on behalf of COVID-19 Genomics Consortium UK (CoG-UK). (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. virological.org .</Citation></Reference><Reference><Citation>England, P. H. (2020). VOC 202012/01 Technical Briefing 5.</Citation></Reference><Reference><Citation>Public Health England (2021). Technical Briefing 6, Investigation of SARS-CoV-2 Variants of Concern. In P. H. England (Ed.).</Citation></Reference><Reference><Citation>Kemp, S. A., Meng, B., Ferriera, I. A., Datir, R., Harvey, W. T., Papa, G., Lytras, S., Collier, D. A., Mohamed, A., Gallo, G., Thakur, N., Carabelli, A. M., Kenyon, J. C. Lever, A. M., De Marco, A., Saliba, C., Culap, K., Cameroni, E., Piccoli, L., … Gupta, R. K. (2021). Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70. bioRxiv. https://doi.org/10.1101/2020.12.14.422555 .</Citation></Reference><Reference><Citation>Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., King, N. P., Veesler, D., &amp; Bloom, J. D. (2020). Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell, 182(5), 1295–1310 e20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7418704</ArticleId><ArticleId IdType="pmcid">7418704</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, C. E. Z., Seah, S. G. K., Chye, D. H., Massey, S., Torres, M., Lim, A. P. C., Wong, S. K. K., Neo, J. J. Y., Wong, P. S., Lim, J. H., Loh, G. S. L., Wang, D. L., Boyd-Kirkup, J. D., Guan, S., Thakkar, D., Teo, G. H., Purushotorman, K., Hutchinson, P. E., Young, B. E., … Hanson, B. J. (2020). The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. bioRxiv. https://doi.org/10.1101/2020.10.26.355107 .</Citation></Reference><Reference><Citation>Horby, P., Bell, I., Breuer, J., Cevik, M., Challen, R., Davies, N., Dabrera, G., Edmunds, J., Ferguson, N., Sebastian, F., Hayward, A., Hippisley-Cox, J., Huntley, C., Humberstone,, B., Huntley, C., McMenamin, J., McKeigue, P., Medley, G., Semple, C. (2021). NERVTAG note on B.1.1.7 severity.</Citation></Reference><Reference><Citation>Calistri, P., Amato, L., Puglia, I., Cito, F., Di Giuseppe, A., Danzetta, M. L., Morelli, D., Di Domenico, M., Caporale, M., Scialabba, S., Portanti, O., Curini, V., Perletta, F., Camma, C., Ancora, M., Savini, G., Migliorati, G., D’Alterio, N., &amp; Lorusso, A. (2021). Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. International Journal of Infectious Diseases, 105, 753–755.</Citation><ArticleIdList><ArticleId IdType="pubmed">33684558</ArticleId><ArticleId IdType="pmcid">7934691</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2021.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Klaser, K., Canas, L. S., Molteni, E., Modat, M., Drew, D. A., Nguyen, L. H., Polidori, L., Selvachandran, S., Hu, C., Capdevila, J., C.-G.U. Consortium, Hammers, A., Chan, A. T., … Ourselin, S. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. Lancet Public Health, 6, e335–e345.</Citation><ArticleIdList><ArticleId IdType="pubmed">33857453</ArticleId><ArticleId IdType="pmcid">8041365</ArticleId><ArticleId IdType="doi">10.1016/S2468-2667(21)00055-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone, M., Thomas, K., Hatch, R., Tan, P. S., Coupland, C., Liao, W., Mouncey, P., Harrison, D., Rowan, K., Horby, P., Watkinson, P., &amp; Hippisley-Cox, J. (2021). Analysis of severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch databases. medRxiv. https://doi.org/10.1101/2021.03.11.21253364 .</Citation></Reference><Reference><Citation>Brookman, S., Cook, J., Zucherman, M., Broughton, S., Harman, K., &amp; Gupta, A. (2021). Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people. The Lancet Child &amp; Adolescent Health, 5(4), e9–e10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00030-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Munitz, A., Yechezkel, M., Dickstein, Y., Yamin, D., &amp; Gerlic, M. (2021). BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high risk populations in Israel. Cell Reports Medicine, 2, 100264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33899031</ArticleId><ArticleId IdType="pmcid">8053239</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2021.100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., Gilchuk, P., Zost, S. J., Tahan, S., Droit, L., Turner, J. S., Kim, W., Schmitz, A. J., Thapa, M., Wang, D., … Diamond, M. S. (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 27, 717–726.</Citation><ArticleIdList><ArticleId IdType="pubmed">33664494</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01294-w</ArticleId><ArticleId IdType="pmcid">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., &amp; Bloom, J. D. (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host &amp; Microbe, 29(3), 463–476 e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N., &amp; Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine, 27(4), 622–625.</Citation><ArticleIdList><ArticleId IdType="pubmed">33654292</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pmcid">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., Graham, B. S., Mascola, J. R., Chang, J. Y., Yin, M. T., Sobieszczyk, M., Kyratsous, C. A., Shapiro, L., Sheng, Z., Huang, Y., &amp; Ho, D. D. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 593(7857), 130–135. https://doi.org/10.1038/s41586-021-03398-2 .</Citation></Reference><Reference><Citation>Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., Oliveira, T. Y., Yang, Z., Abernathy, M. E., Huey-Tubman, K. E., Hurley, A., Turroja, M., West, K. A., Gordon, K., Millard, K. G., … Nussenzweig, M. C. (2021). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 592, 616–622.</Citation><ArticleIdList><ArticleId IdType="pubmed">33567448</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03324-6</ArticleId><ArticleId IdType="pmcid">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H. H., Michailidis, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Luchsinger, L., Hillyer, C. D., Caskey, M., … Bieniasz, P. D. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife, 9, e61312.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723407</ArticleId><ArticleId IdType="pmcid">7723407</ArticleId><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G., Franco, L. A. M., Ramundo, M. S., de Jesus, J. G., Andrade, P. S. Coletti, T. M., Ferreira, G. M., Silva, C. A. M., Manuli, E. R., … Sabino, E. C. (2021). Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. Science, 372(6544), 815–821. https://doi.org/10.1126/science.abh2644 .</Citation></Reference><Reference><Citation>Wang, G. L., Wang, Z. Y., Duan, L. J., Meng, Q. C., Jiang, M. D., Cao, J., Yao, L., Zhu, K. L., Cao, W. C., &amp; Ma, M. J. (2021). Susceptibility of circulating SARS-CoV-2 variants to neutralization. New England Journal of Medicine. https://doi.org/10.1056/NEJMc2103022 .</Citation></Reference><Reference><Citation>Hoffmann, M., Arora, P., Gross, R., Seidel, A., Hornich, B. F., Hahn, A. S., Kruger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., Winkler, M. S., Schulz, S., Jack, H. M., Jahrsdorfer, B., Schrezenmeier, H., Muller, M., Kleger, A., Munch, J., &amp; Pohlmann, S. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 184, 2384–2393.e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7980144</ArticleId><ArticleId IdType="pmcid">7980144</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.03.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-Gonzalez, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., Reddy, N. P., Sanchez San Martin, C., Federman, S., Cheng, J., Balcerek, J., Taylor, J., Streithorst, J. A., Miller, S., Kumar, G. R., … Chiu, C. Y. (2021). Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant. Cell. https://doi.org/10.1016/j.cell.2021.04.025 .</Citation></Reference><Reference><Citation>Tchesnokova, V., Kulakesara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., Kutumbaka, K., Geng, H., Fowler, C., Greene, D., Ralston, J., Samadpour, M., &amp; Sokurenko, E. (2021). Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv. https://doi.org/10.1101/2021.02.22.432189 .</Citation></Reference><Reference><Citation>McCallum, M., Bassi, J., Marco, A., Chen, A., Walls, A. C., Iulio, J. D., Tortorici, M. A., Navarro, M. J., Silacci-Fregni, C., Saliba, C., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., … Veesler, D. (2021). SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. https://doi.org/10.1101/2021.03.31.437925 .</Citation></Reference><Reference><Citation>Annavajhala, M. K., Mohri, H., Zucker, J. E., Sheng, Z., Wang, P., Gomez-Simmonds, A., Ho, D. D., &amp; Uhlemann, A. C. (2021). A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv. https://doi.org/10.1101/2021.02.23.21252259 .</Citation></Reference><Reference><Citation>Edara, V. V., Lai, L., Sahoo, M. K., Floyd, K., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnack. S., Stephens, K., Mokhtari, E. B., Mudvari, P., Creanga, A., Pegu, A., Derrien-Colemyn, A., Henry, A. R., Gagne, M., Graham, B. S., Wrammert, J., Douek, D. C., Boritz, E., Pinsky. B. A., Suthar, M. S. (2021). Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. https://doi.org/10.1101/2021.05.09.443299 .</Citation></Reference><Reference><Citation>Volkan, E., &amp; Volkan, E. (2020). Under the COVID-19 lockdown: Rapid review about the unique case of North Cyprus. Psychological Trauma, 12(5), 539–541.</Citation><ArticleIdList><ArticleId IdType="pubmed">32551776</ArticleId><ArticleId IdType="doi">10.1037/tra0000809</ArticleId><ArticleId IdType="pmcid">32551776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., &amp; McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">7164637</ArticleId><ArticleId IdType="pmcid">7164637</ArticleId><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson, R., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Gobeil, S. M. C., Kopp, M., Li, D., Parks, R., Hsu, A. L., Borgnia, M. J., Haynes, B. F., &amp; Acharya, P. (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nature Structural &amp; Molecular Biology, 27(10), 925–933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-0479-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W. P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., &amp; McLellan, J. S. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences USA, 114(35), E7348–E7357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707304114</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Perez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., Hammitt, L. L., … C.C.T. Group. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik, A., Wallisch, A. K., Sanger, B., Swanson, K. A., Muhl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Tureci, O., Dormitzer, P. R., &amp; Sahin, U. (2021). Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science, 371(6534), 1152–1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">7971771</ArticleId><ArticleId IdType="pmcid">7971771</ArticleId><ArticleId IdType="doi">10.1126/science.abg6105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., &amp; Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId><ArticleId IdType="pmcid">32225176</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., 3rd., Leist, S. R., Schafer, A., Nakajima, N., Takahashi, K., Lee, R. E., Mascenik, T. M., Graham, R., Edwards, C. E., Tse, L. V., Okuda, K., Markmann, A. J., Bartelt, L., de Silva, A., … Baric, R. S. (2020). SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 370(6523), 1464–1468.</Citation><ArticleIdList><ArticleId IdType="pubmed">33184236</ArticleId><ArticleId IdType="pmcid">7775736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert, S. C. (2012). T-cell-inducing vaccines—What’s the future. Immunology, 135(1), 19–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">22044118</ArticleId><ArticleId IdType="pmcid">3246649</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2567.2011.03517.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., … Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 369(6499), 77–81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnafous, P., Nicolai, M. C., Taveau, J. C., Chevalier, M., Barriere, F., Medina, J., Le Bihan, O., Adam, O., Ronzon, F., &amp; Lambert, O. (2014). Treatment of influenza virus with beta-propiolactone alters viral membrane fusion. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1838(1 Pt B), 355–363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2013.09.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., &amp; Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(2), 181–192.</Citation><ArticleIdList><ArticleId IdType="pubmed">33217362</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmcid">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, C., Mendonca, L., Yang, Y., Gao, Y., Shen, C., Liu, J., Ni, T., Ju, B., Liu, C., Tang, X., Wei, J., Ma, X., Zhu, Y., Liu, W., Xu, S., Liu, Y., Yuan, J., Wu, J., Liu, Z., … Zhang, P. (2020). The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by Cryo-EM and Cryo-ET. Structure, 28(11), 1218–1224 e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33058760</ArticleId><ArticleId IdType="pmcid">7557167</ArticleId><ArticleId IdType="doi">10.1016/j.str.2020.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Anywaine, Z., Whitworth, H., Kaleebu, P., Praygod, G., Shukarev, G., Manno, D., Kapiga, S., Grosskurth, H., Kalluvya, S., Bockstal, V., Anumendem, D., Luhn, K., Robinson, C., Douoguih, M., &amp; Watson-Jones, D. (2019). Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. The Journal of Infectious Diseases, 220(1), 46–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30796818</ArticleId><ArticleId IdType="pmcid">6548900</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiz070</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, K., Bastian, A. R., Feldman, R. A., Omoruyi, E., de Paepe, E., Hendriks, J., van Zeeburg, H., Godeaux, O., Langedijk, J. P. M., Schuitemaker, H., Sadoff, J., &amp; Callendret, B. (2020). Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged &gt;/=60 years. The Journal of Infectious Diseases, 222(6), 979–988.</Citation><ArticleIdList><ArticleId IdType="pubmed">32320465</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiaa193</ArticleId><ArticleId IdType="pmcid">32320465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P. J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. New England Journal of Medicine, 384, 1824–1835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034201</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lubbe, J. E. M., Rosendahl Huber, S. K., Vijayan, A., Dekking, L., van Huizen, E., Vreugdenhil, J., Choi, Y., Baert, M. R. M., Feddes-de Boer, K., Izquierdo Gil, A., van Heerden, M., Dalebout, T. J., Myeni, S. K., Kikkert, M., Snijder, E. J., de Waal, L., Stittelaar, K. J., Tolboom, J., Serroyen, J., … Wegmann, F. (2021). Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. NPJ Vaccines, 6(1), 39.</Citation><ArticleIdList><ArticleId IdType="pubmed">33741993</ArticleId><ArticleId IdType="pmcid">7979827</ArticleId><ArticleId IdType="doi">10.1038/s41541-021-00301-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer, K. J., Barrett, J. R., Belij-Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R., Flaxman, A., Wright, D., Bellamy, D., Bittaye, M., Dold, C., Provine, N. M., Aboagye, J., Fowler, J., Silk, S. E., Alderson, J., Aley, P. K., Angus, B., Berrie, E., … C.V.T.G. Oxford. (2021). T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 27(2), 270–278.</Citation><ArticleIdList><ArticleId IdType="pubmed">33335323</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-01194-5</ArticleId><ArticleId IdType="pmcid">33335323</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … C.V.T.G. Oxford. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), 99–111.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723445</ArticleId><ArticleId IdType="pmcid">7723445</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J. N., Bhorat, A. E., du Plessis, J., Esmail, A., … N.-S.G.W.-V.C. Group. (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine, 384, 1885–1898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102214</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., … Moore, P. L. (2021). Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine, 384(22), 2161–2163. https://doi.org/10.1056/NEJMc2104192 .</Citation></Reference><Reference><Citation>Castelli, G. P., Pognani, C., Sozzi, C., Franchini, M., &amp; Vivona, L. (2021). Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19. Critical Care, 25(1), 137.</Citation><ArticleIdList><ArticleId IdType="pubmed">33845870</ArticleId><ArticleId IdType="pmcid">8039796</ArticleId><ArticleId IdType="doi">10.1186/s13054-021-03572-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir, K. L., Kallam, A., Koepsell, S. A., &amp; Gundabolu, K. (2021). Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. New England Journal of Medicine, 384, 1964–1965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2105869</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicherla, C. B., Pauley, R. A., de Havenon, A., Yaghi, S., Ishida, K., &amp; Torres, J. L. (2020). Cerebral venous sinus thrombosis in the COVID-19 pandemic. Journal of Neuro-Ophthalmology, 40(4), 457–462.</Citation><ArticleIdList><ArticleId IdType="pubmed">33186264</ArticleId><ArticleId IdType="doi">10.1097/WNO.0000000000001122</ArticleId><ArticleId IdType="pmcid">33186264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, C., Nichols, T., Pike, M., Subbe, C., &amp; Elghenzai, S. (2020). Cerebral venous sinus thrombosis as a presentation of COVID-19. European Journal of Case Reports in Internal Medicine, 7(5), 001691.</Citation><ArticleIdList><ArticleId IdType="pubmed">32399457</ArticleId><ArticleId IdType="pmcid">7213833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bompard, F., Monnier, H., Saab, I., Tordjman, M., Abdoul, H., Fournier, L., Sanchez, O., Lorut, C., Chassagnon, G., &amp; Revel, M. P. (2020). Pulmonary embolism in patients with COVID-19 pneumonia. European Respiratory Journal, 56(1), 2001365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01365-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, X., Tang, H., Pajon, R., Smith, G., Glenn, G. M., Shi, W., Korber, B., &amp; Montefiori, D. C. (2021). Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. New England Journal of Medicine. https://doi.org/10.1056/NEJMc2103740. .</Citation></Reference><Reference><Citation>Kalimuddin, S., Tham, C. Y., Qui, M., de Alwis, R., Sim, J. X., Lim, J. M., Tan, H. C., Syenina, A., Zhang, S. L., Le Bert, N., Tan, A. T., Leong, Y. S., Yee, J. X., Ong, E. Z., Ooi, E. E., Bertoletti, A., &amp; Low, J. G. (2021). Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med (N Y). https://doi.org/10.1016/j.medj.2021.04.003 .</Citation></Reference><Reference><Citation>Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., &amp; Shan, H. (2020). Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology, 158(6), 1831–1833 e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32142773</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.02.055</ArticleId><ArticleId IdType="pmcid">32142773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, E. W., Zachariah, P., Gorelik, M., Boneparth, A., Kernie, S. G., Orange, J. S., &amp; Milner, J. D. (2020). Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA, 324(3), 294–296.</Citation><ArticleIdList><ArticleId IdType="pubmed">32511676</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.10374</ArticleId><ArticleId IdType="pmcid">32511676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao, R., Qiu, Y., He, J. S., Tan, J. Y., Li, X. H., Liang, J., Shen, J., Zhu, L. R., Chen, Y., Iacucci, M., Ng, S. C., Ghosh, S., &amp; Chen, M. H. (2020). Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. The Lancet Gastroenterology &amp; Hepatology, 5(7), 667–678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30126-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann, D., Sperhake, J. P., Lutgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schroder, A. S., Burdelski, C., de Heer, G., Nierhaus, A., Frings, D., Pfefferle, S., Becker, H., Bredereke-Wiedling, H., de Weerth, A., Paschen, H. R., … Kluge, S. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Annals of Internal Medicine, 173(4), 268–277.</Citation><ArticleIdList><ArticleId IdType="pubmed">32374815</ArticleId><ArticleId IdType="doi">10.7326/M20-2003</ArticleId><ArticleId IdType="pmcid">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497–506.</Citation><ArticleIdList><ArticleId IdType="pubmed">7159299</ArticleId><ArticleId IdType="pmcid">7159299</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde Cardona, G., Quintana Pajaro, L. D., Quintero Marzola, I. D., Ramos Villegas, Y., &amp; Moscote Salazar, L. R. (2020). Neurotropism of SARS-CoV 2: Mechanisms and manifestations. Journal of the Neurological Sciences, 412, 116824.</Citation><ArticleIdList><ArticleId IdType="pubmed">32299010</ArticleId><ArticleId IdType="pmcid">7141641</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.116824</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., Miao, X., Li, Y., &amp; Hu, B. (2020). Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology, 77(6), 683–690.</Citation><ArticleIdList><ArticleId IdType="pubmed">32275288</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmcid">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. L., Dhakal, S., Ursin, R. L., Deshpande, S., Sandberg, K., &amp; Mauvais-Jarvis, F. (2020). Biological sex impacts COVID-19 outcomes. PLoS Pathogens, 16(6), e1008570.</Citation><ArticleIdList><ArticleId IdType="pubmed">32569293</ArticleId><ArticleId IdType="pmcid">7307725</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1008570</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, Y., Wu, P., Lu, W., Liu, K., Ma, K., Huang, L., Cai, J., Zhang, H., Qin, Y., Sun, H., Ding, W., Gui, L., &amp; Wu, P. (2020). Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. PLoS Pathogens, 16(4), e1008520.</Citation><ArticleIdList><ArticleId IdType="pubmed">32343745</ArticleId><ArticleId IdType="pmcid">7209966</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1008520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J., Ji, H., Zheng, W., Wu, X., Zhu, J. J., Arnold, A. P., &amp; Sandberg, K. (2010). Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent. Biology of Sex Differences, 1(1), 6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208466</ArticleId><ArticleId IdType="pmcid">3010099</ArticleId><ArticleId IdType="doi">10.1186/2042-6410-1-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkonen, L., Pihlajamaa, P., Sahu, B., Zhang, F. P., &amp; Janne, O. A. (2010). Androgen receptor and androgen-dependent gene expression in lung. Molecular and Cellular Endocrinology, 317(1–2), 14–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035825</ArticleId><ArticleId IdType="doi">10.1016/j.mce.2009.12.022</ArticleId><ArticleId IdType="pmcid">20035825</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen, M. D., de Graaf, E. L., Sonneveld, M. E., Plomp, H. R., Nouta, J., Hoepel, W., Chen, H. J., Linty, F., Visser, R., Brinkhaus, M., Sustic, T., de Taeye, S. W., Bentlage, A. E. H., Toivonen, S., Koeleman, C. A. M., Sainio, S., Kootstra, N. A., Brouwer, P. J. M., Geyer, C. E., … Vidarsson, G. (2021). Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science, 371(6532), eabc8378. https://doi.org/10.1126/science.abc8378 .</Citation></Reference><Reference><Citation>Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R., Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, U., Dugan, H., Wilson, P. C., Pham, T. D., Boyd, S. D., Nadeau, K. C., Pinsky, B. A., … Wang, T. T. (2021). Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature Immunology, 22(1), 67–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33169014</ArticleId><ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId><ArticleId IdType="pmcid">33169014</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. L., Pekosz, A., Park, H. S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., Shrestha, R., Wu, A. A., Hughes, R. M., Burgess, I., Caturegli, P., Laeyendecker, O., Quinn, T. C., Sullivan, D., Shoham, S., … Tobian, A. A. (2020). Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. The Journal of Clinical Investigation, 130(11), 6141–6150.</Citation><ArticleIdList><ArticleId IdType="pubmed">32764200</ArticleId><ArticleId IdType="pmcid">7598041</ArticleId><ArticleId IdType="doi">10.1172/JCI142004</ArticleId></ArticleIdList></Reference><Reference><Citation>Asselta, R., Paraboschi, E. M., Mantovani, A., &amp; Duga, S. (2020). ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY), 12(11), 10087–10098.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103415</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryamohan, K., Diwanji, D., Stawiski, E. W., Gupta, R., Miersch, S., Liu, J., Chen, C., Jiang, Y. P., Fellouse, F. A., Sathirapongsasuti, J. F., Albers, P. K., Deepak, T., Saberianfar, R., Ratan, A., Washburn, G., Mis, M., Santhosh, D., Somasekar, S., Hiranjith, G. H., … Seshagiri, S. (2021). Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Communications Biology, 4(1), 475.</Citation><ArticleIdList><ArticleId IdType="pubmed">33846513</ArticleId><ArticleId IdType="pmcid">8041869</ArticleId><ArticleId IdType="doi">10.1038/s42003-021-02030-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson, W. T., Evans, D. M. An, J., &amp; Jones, S. J. (2020). ACE 2 coding variants: A potential X-linked risk factor for COVID-19 disease. bioRxiv. https://doi.org/10.1101/2020.04.05.026633 .</Citation></Reference><Reference><Citation>Weissman, D., Alameh, M. G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., … Montefiori, D. C. (2021). D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host &amp; Microbe, 29(1), 23–31 e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, A., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., Rey, S. M., Nicholls, S. M., Colquhoun, R. M., da Silva Filipe, A., Shepherd, J., Pascall, D. J., Shah, R., Jesudason, N., Li, K., … Connor, T. R. (2021). Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell, 184(1), 64–75 e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275900</ArticleId><ArticleId IdType="pmcid">7674007</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.11.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., Hastie, K. M., Parker, M. D., Partridge, D. G., Evans, C. M., Freeman, T. M., de Silva, T. I., Sheffield, C.-G.G., McDanal, C., Perez, L. G., … Montefiori, D. C. (2020). Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell, 182(4), 812–827 e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">32697968</ArticleId><ArticleId IdType="pmcid">32697968</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., &amp; Wu, J. T. (2021). Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance, 26(1), 2002106.</Citation><ArticleIdList><ArticleId IdType="pmcid">7791602</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.26.1.2002106</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Munnink, B. B., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Munger, E., Molenkamp, R., van der Spek, A., Tolsma, P., Rietveld, A., Brouwer, M., Bouwmeester-Vincken, N., Harders, F., Hakze-van der Honing, R., Wegdam-Blans, M. C. A., Bouwstra, R. J., GeurtsvanKessel, C., van der Eijk, A. A., Velkers, F. C., Smit, L. A. M., … Koopmans, M. P. G. (2021). Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science, 371(6525), 172–177.</Citation><ArticleIdList><ArticleId IdType="pubmed">33172935</ArticleId><ArticleId IdType="doi">10.1126/science.abe5901</ArticleId><ArticleId IdType="pmcid">33172935</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarthy, L. R., Bain, W. G., Haidar, G., &amp; Duprex, W. P. (2021). Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. bioRxiv, 371(6534), 1139–1142. https://doi.org/10.1126/science.abf6950 .</Citation></Reference><Reference><Citation>Eurosurveillance editorial team. (2021). Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA—First update. Eurosurveillance, 26(3), 2101211.</Citation><ArticleIdList><ArticleId IdType="pmcid">7848680</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>